Biogen, with $5.6B Apellis buy, builds out immunology offerings
BioPharma Dive
Chief Financial Officer Robin Kramer explained how the deal not only provides two marketed products, but a team with nephrology expertise that will be valuable as Biogen prepares to launch felzartamab
pharminent
March 31, 2026 (Last updated: April 1, 2026)
BioPharma Dive
Chief Financial Officer Robin Kramer explained how the deal not only provides two marketed products, but a team with nephrology expertise that will be valuable as Biogen prepares to launch felzartamab